June 15, 2022 – Sysmex America has received FDA clearance for the addition of residual white blood cell counting to its XN-10 Automated Hematology Analyzer with Blood Bank mode. This is the first and only automated hematology analyzer to be FDA-cleared for residual WBC counting. The latest analyzer supports red blood cell (RBC) and platelet (PLT) component testing along with residual white blood cell counting in a single sample aspiration, providing blood processing centers with increased efficiency, consistency and accuracy.
Blood component quality is key in transfusion medicine and blood product manufacturing. Sysmex America’s XN-10 with Blood Bank mode is a holistic solution that offers accurate cell counts on products that are key to blood centers and blood banks. With no sample preparation or pre-dilution required, the XN-10 with Blood Bank mode provides precise and rapid cell counts for greater confidence in blood product quality.
The XN-10 with Blood Bank mode features analysis of blood components with four different selectable profiles – two profiles for red blood cell concentrates and two profiles for platelet concentrates.
“Sysmex America’s XN-10 Automated Hematology Analyzer with Blood Bank mode is a holistic solution that covers donors, patients and blood components,” said Andy Hay, chief executive officer of Sysmex America. “The XN-10’s standardized, consistent and automated assessment of blood product quality ensures patient safety.”
Available as a single module (XN-1000BB) or twin co-primary analyzers (XN-2000BB), the scalable hematology analyzer may be installed as a tabletop analyzer or placed on wagons, and either model may be made even more efficient with the addition of the RU-20™ reagent unit.